title: Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor-related protein.
abstract: The interaction between the endocytic receptor low density lipoprotein receptor-related protein (LRP) and either coagulation factor IX or its active derivative factor IXa was studied. Purified factor IX was unable to associate with LRP when analyzed by surface plasmon resonance. By contrast, factor XIa-mediated conversion of factor IX into factor IXa resulted in reversible dose- and calcium-dependent binding to LRP. Active-site blocking of factor IXa did not affect binding to LRP, whereas LRP binding was efficiently inhibited in the presence of heparin or antibodies against factor IX or LRP. The factor IXa-LRP interaction could be described by a 2-site binding model with equilibrium dissociation constants of 27 nmol/L and 69 nmol/L. Consistent with this model, it was observed that factor IXa binds to 2 different recombinant receptor fragments of LRP (denoted cluster II and cluster IV) with equilibrium dissociation constants of 227 nmol/L and 53 nmol/L, respectively. The amount of factor IXa degraded by LRP-deficient cells was 35% lower than by LRP-expressing cells, demonstrating that LRP contributes to the transport of factor IXa to the intracellular degradation pathway. Because ligand binding to LRP is often preceded by binding to proteoglycans, the contribution of proteoglycans to the catabolism of factor IXa was addressed by employing proteoglycan-deficient cells. Degradation of factor IXa by proteoglycan-deficient cells proceeded at a 83% lower rate than wild-type cells. In conclusion, the data presented here indicate that both LRP and proteoglycans have the potential to contribute to the catabolism of factor IXa.
authors.affiliation: Department of Biochemistry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
authors.forename: J G
authors.initials: JG
authors.lastname: Neels
authors.forename: B M
authors.initials: BM
authors.lastname: van Den Berg
authors.forename: K
authors.initials: K
authors.lastname: Mertens
authors.forename: H
authors.initials: H
authors.lastname: ter Maat
authors.forename: H
authors.initials: H
authors.lastname: Pannekoek
authors.forename: A J
authors.initials: AJ
authors.lastname: van Zonneveld
authors.forename: P J
authors.initials: PJ
authors.lastname: Lenting
mesh_terms: D000818:Animals; D000906:Antibodies / Q000276:immunology; D001665:Binding Sites; D016466:CHO Cells / Q000737:chemistry / Q000378:metabolism; D006224:Cricetinae; D004792:Enzyme Precursors / Q000737:chemistry / Q000378:metabolism; D005164:Factor IX / Q000737:chemistry / Q000276:immunology / Q000378:metabolism*; D015949:Factor IXa / Q000737:chemistry / Q000378:metabolism; D006493:Heparin / Q000494:pharmacology; D026541:Heymann Nephritis Antigenic Complex; D006801:Humans; D007700:Kinetics; D008562:Membrane Glycoproteins / Q000276:immunology / Q000378:metabolism / Q000502:physiology; D010446:Peptide Fragments; D011509:Proteoglycans / Q000502:physiology; D011994:Recombinant Proteins; D020349:Surface Plasmon Resonance
chemical_list: D000906:Antibodies; D004792:Enzyme Precursors; D026541:Heymann Nephritis Antigenic Complex; D008562:Membrane Glycoproteins; D010446:Peptide Fragments; D011509:Proteoglycans; D011994:Recombinant Proteins; D005164:Factor IX; D006493:Heparin; D015949:Factor IXa